Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of sildenafil 20 mg TID in pulmonary arterial hypertension
2014-004167-20Phase 3
- Sponsor
- Pfizer
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sildenafil in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Primary endpoint: Change in 6-minute walk distance at Week 12.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2014-004167-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004167-20.